TARS

SEC source: 0001209191-21-051193 · doc4.xml · nonDerivative · entry 1

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,227,348

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.030 to $25.250, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-051191 · doc4.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,227,438

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $25.000 to $25.275. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

SEC source: 0001209191-21-051191 · doc4.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,229,355

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

SEC source: 0001209191-21-050631 · doc4.xml · nonDerivative · entry 2

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,227,969

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.

SEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 3

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,229,458

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

SEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,229,558

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

SEC source: 0001209191-21-050631 · doc4.xml · nonDerivative · entry 1

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,228,669

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.

SEC source: 0001209191-21-050626 · doc4.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,230,285

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

SEC source: 0001209191-21-050177 · doc4.xml · nonDerivative · entry 3

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,231,798

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.

SEC source: 0001209191-21-050177 · doc4.xml · nonDerivative · entry 2

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,231,898

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.

SEC source: 0001209191-21-050177 · doc4.xml · nonDerivative · entry 1

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,231,998

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.

SEC source: 0001209191-21-050176 · doc4.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Bobak Azamian Living Trust established April 16, 2018

Disclosed balance after: 1,231,901

F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2021.

F2 · ownership.nature: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.

SEC source: 0001213900-21-034310 · ownership.xml · nonDerivative · entry 3

Vivo Capital IX, LLC · CIK 0001750698 · 10% owner

Vivo Capital Fund IX, L.P. · CIK 0001750117 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,987,331

F3 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.0 to $29.5, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

F4 · ownership.nature: The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

SEC source: 0001213900-21-034310 · ownership.xml · nonDerivative · entry 2

Vivo Capital IX, LLC · CIK 0001750698 · 10% owner

Vivo Capital Fund IX, L.P. · CIK 0001750117 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,995,035

F2 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2 to $29.7, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4 · ownership.nature: The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

SEC source: 0001213900-21-034310 · ownership.xml · nonDerivative · entry 1

Vivo Capital IX, LLC · CIK 0001750698 · 10% owner

Vivo Capital Fund IX, L.P. · CIK 0001750117 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,005,035

F1 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.6 to $28.3, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F4 · ownership.nature: The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

SEC source: 0001213900-21-034298 · ownership.xml · nonDerivative · entry 2

Vivo Capital IX, LLC · CIK 0001750698 · 10% owner

Vivo Capital Fund IX, L.P. · CIK 0001750117 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,043,015

F2 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.0 to $28.1, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · ownership.nature: The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

SEC source: 0001213900-21-034298 · ownership.xml · nonDerivative · entry 1

Vivo Capital IX, LLC · CIK 0001750698 · 10% owner

Vivo Capital Fund IX, L.P. · CIK 0001750117 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,153,015

F1 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.1 to $29.0, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

F3 · ownership.nature: The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

SEC source: 0001209191-21-041713 · doc4.xml · derivative · entry 2

Tester Jason E. · CIK 0001827272 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F2 · derivative.exercise_date: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

SEC source: 0001209191-21-041713 · doc4.xml · derivative · entry 1

Tester Jason E. · CIK 0001827272 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001209191-21-041715 · doc4.xml · derivative · entry 1

YARNO WENDY L · CIK 0001181186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001209191-21-041712 · doc4.xml · derivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F2 · derivative.exercise_date: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

SEC source: 0001209191-21-041712 · doc4.xml · derivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001209191-21-041705 · doc4.xml · derivative · entry 2

Goldberg Andrew D. · CIK 0001827722 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F2 · derivative.exercise_date: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

SEC source: 0001209191-21-041705 · doc4.xml · derivative · entry 1

Goldberg Andrew D. · CIK 0001827722 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2031-06-15

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001209191-21-041702 · doc4.xml · derivative · entry 2

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F2 · derivative.exercise_date: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

SEC source: 0001209191-21-041702 · doc4.xml · derivative · entry 1

CHAUDHURI BHASKAR · CIK 0001458643 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001209191-21-041701 · doc4.xml · derivative · entry 4

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,257

Underlying: Common Stock · 4,257 shares

Expires not disclosed

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F5 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001209191-21-041701 · doc4.xml · derivative · entry 3

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F3 · derivative.exercise_date: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

SEC source: 0001209191-21-041701 · doc4.xml · derivative · entry 2

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-06-15

F2 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

SEC source: 0001209191-21-041701 · doc4.xml · nonDerivative · entry 1

Ackermann Michael · CIK 0001791249 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,233,181

F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The RSUs are fully vested as of the date of grant.

SEC source: 0001493152-21-010811 · ownership.xml · nonDerivative · entry 1

RTW INVESTMENTS, LP · CIK 0001493215 · 10% owner

WONG RODERICK · CIK 0001493280 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By RTW

Disclosed balance after: 2,013,601

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Dr. Wong disclaims beneficial ownership of the reported securities held by the Funds, except to the extent of his pecuniary interest therein.

SEC source: 0001213900-21-021965 · ownership.xml · nonDerivative · entry 1

Vivo Capital IX, LLC · CIK 0001750698 · 10% owner

Vivo Capital Fund IX, L.P. · CIK 0001750117 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,244,635

F1 · kind: The reporting person inadvertently sold 400 shares of Tarsus Pharmaceuticals, Inc.'s common stock reported herein, which was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the reporting person's purchase of 400 shares of Tarsus Pharmaceuticals, Inc.'s common stock at a price of $16 per share in connection with the initial public offering on October 20, 2020. The reporting person has agreed to pay to Tarsus Pharmaceuticals, Inc., upon settlement of the sale, $5,735.93, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.

F2 · price: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.25 to $30.50, inclusive. The reporting person undertakes to provide to Tarsus Pharmaceuticals, Inc., any security holder of Tarsus Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F3 · ownership.nature: The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Jack Nielsen, Mahendra Shah and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

SEC source: 0001209191-21-018041 · doc4.xml · derivative · entry 1

Holdbrook Mark J. · CIK 0001827564 · V.P., Clinical Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,300

Underlying: Common Stock · 14,300 shares

Expires 2031-03-02

F1 · derivative.exercise_date: Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan. 25% of the option shares shall vest and become exercisable on March 2, 2022, and 1/48th of the option shares shall vest and become exercisable each month thereafter for a period of 3 years.

SEC source: 0001209191-21-006987 · doc4.xml · derivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,368

Underlying: Common Stock · 89,368 shares

Expires 2031-02-02

F1 · derivative.exercise_date: Option granted under the Tarsus Pharmaceuticals, Inc. 2020 Equity Incentive Plan. 25% of the option shares shall vest and become exercisable on January 19, 2022, and 1/48th of the option shares shall vest and become exercisable each month thereafter for a period of 3 years.

SEC source: 0001209191-21-002747 · doc4.xml · derivative · entry 1

Greenstein Leonard M. · CIK 0001519692 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,999

Underlying: Common Stock · 40,999 shares

Expires 2031-01-06

F1 · derivative.exercise_date: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years.

SEC source: 0001209191-21-002744 · doc4.xml · derivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,499

Underlying: Common Stock · 61,499 shares

Expires 2031-01-06

F1 · derivative.exercise_date: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years.

SEC source: 0001209191-21-002741 · doc4.xml · derivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,999

Underlying: Common Stock · 40,999 shares

Expires 2031-01-06

F1 · derivative.exercise_date: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years.

SEC source: 0001209191-21-002738 · doc4.xml · derivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 204,998

Underlying: Common Stock · 204,998 shares

Expires 2031-01-06

F1 · derivative.exercise_date: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years.

SEC source: 0001209191-21-002731 · doc4.xml · derivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,368

Underlying: Common Stock · 89,368 shares

Expires 2031-01-06

F1 · derivative.exercise_date: 25% of the option shares shall vest on January 4, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years.

SEC source: 0001209191-20-060086 · doc4.xml · derivative · entry 1

YARNO WENDY L · CIK 0001181186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-11-18

F1 · derivative.exercise_date: The option shares vest in 3 annual installments beginning on November 19, 2021.

SEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 12

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Adam S. Horowitz Revocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 7,396 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.

SEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 11

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Adam S. Horowitz Revocable Trust

Disclosed balance after: 0

Underlying: Common Stock · 43,151 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.

SEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 10

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71,427 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

SEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 9

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 245,966 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

SEC source: 0001209191-20-055424 · doc4.xml · derivative · entry 8

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,434,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

SEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 7

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Adam S. Horowitz Revocable Trust

Disclosed balance after: 66,172

F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.

SEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 6

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Adam S. Horowitz Revocable Trust

Disclosed balance after: 50,547

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.

SEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 5

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Adam S. Horowitz Revocable Trust

Disclosed balance after: 43,151

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held by Adam S. Horowitz Revocable Trust, of which Adam S. Horowitz is Trustee. Adam S. Horowitz is affiliated with Horowitz Limited Partnership VIII.

SEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 4

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,920,933

SEC source: 0001209191-20-055424 · doc4.xml · nonDerivative · entry 3

Horowitz Limited Partnership VIII · CIK 0001827839 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,752,183

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.